232 related articles for article (PubMed ID: 26087197)
1. The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis.
Zhang L; Teng Y; Fan Y; Wang Y; Li W; Shi J; Ma Y; Li C; Shi X; Qu X; Liu Y
Oncotarget; 2015 Sep; 6(26):22918-33. PubMed ID: 26087197
[TBL] [Abstract][Full Text] [Related]
2. E3 Ubiquitin Ligase Cbl-b Prevents Tumor Metastasis by Maintaining the Epithelial Phenotype in Multiple Drug-Resistant Gastric and Breast Cancer Cells.
Xu L; Zhang Y; Qu X; Che X; Guo T; Cai Y; Li A; Li D; Li C; Wen T; Fan Y; Hou K; Ma Y; Hu X; Liu Y
Neoplasia; 2017 Apr; 19(4):374-382. PubMed ID: 28334634
[TBL] [Abstract][Full Text] [Related]
3. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.
Vennin C; Spruyt N; Dahmani F; Julien S; Bertucci F; Finetti P; Chassat T; Bourette RP; Le Bourhis X; Adriaenssens E
Oncotarget; 2015 Oct; 6(30):29209-23. PubMed ID: 26353930
[TBL] [Abstract][Full Text] [Related]
4. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
5. Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer.
Wang J; Liu Y; Wang L; Sun X; Wang Y
Oncotarget; 2016 Feb; 7(5):5564-75. PubMed ID: 26734994
[TBL] [Abstract][Full Text] [Related]
6. RANKL-induced migration of MDA-MB-231 human breast cancer cells via Src and MAPK activation.
Tang ZN; Zhang F; Tang P; Qi XW; Jiang J
Oncol Rep; 2011 Nov; 26(5):1243-50. PubMed ID: 21725611
[TBL] [Abstract][Full Text] [Related]
7. [Inhibitory acting mechanism of psoralen-osthole on bone metastasis of breast cancer--an expatiation viewing from OPG/RANKL/RANK system].
Sheng L; Wu CY; Chen XF
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 May; 31(5):684-9. PubMed ID: 21812275
[TBL] [Abstract][Full Text] [Related]
8. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
9. CBL enhances breast tumor formation by inhibiting tumor suppressive activity of TGF-β signaling.
Kang JM; Park S; Kim SJ; Hong HY; Jeong J; Kim HS; Kim SJ
Oncogene; 2012 Dec; 31(50):5123-31. PubMed ID: 22310290
[TBL] [Abstract][Full Text] [Related]
10. C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
Li W; Xu L; Che X; Li H; Zhang Y; Song N; Wen T; Hou K; Yang Y; Zhou L; Xin X; Xu L; Zeng X; Shi S; Liu Y; Qu X; Teng Y
BMC Cancer; 2018 May; 18(1):507. PubMed ID: 29720121
[TBL] [Abstract][Full Text] [Related]
11. The E3 Ubiquitin Ligase Cbl-b Predicts Favorable Prognosis in Breast Cancer.
Liu X; Teng Y; Wu X; Li Z; Bao B; Liu Y; Qu X; Zhang L
Front Oncol; 2020; 10():695. PubMed ID: 32435620
[No Abstract] [Full Text] [Related]
12. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.
Tan W; Zhang W; Strasner A; Grivennikov S; Cheng JQ; Hoffman RM; Karin M
Nature; 2011 Feb; 470(7335):548-53. PubMed ID: 21326202
[TBL] [Abstract][Full Text] [Related]
13. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.
Azim HA; Peccatori FA; Brohée S; Branstetter D; Loi S; Viale G; Piccart M; Dougall WC; Pruneri G; Sotiriou C
Breast Cancer Res; 2015 Feb; 17():24. PubMed ID: 25849336
[TBL] [Abstract][Full Text] [Related]
14. Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis.
Sévère N; Dieudonné FX; Marty C; Modrowski D; Patiño-García A; Lecanda F; Fromigué O; Marie PJ
J Bone Miner Res; 2012 Oct; 27(10):2108-17. PubMed ID: 22623369
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells.
Tang ZN; Zhang F; Tang P; Qi XW; Jiang J
Biochem Biophys Res Commun; 2011 May; 408(3):411-6. PubMed ID: 21514280
[TBL] [Abstract][Full Text] [Related]
16. E3 ubiquitin ligase Cbl-b suppresses human ORMDL3 expression through STAT6 mediation.
Yang WX; Jin R; Jiang CM; Wang XH; Shu J; Li L; Zhu LH; Zhuang LL; Gao C; Zhou GP
FEBS Lett; 2015 Jul; 589(15):1975-80. PubMed ID: 26112603
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin ligase c-Cbl is involved in tamoxifen-induced apoptosis of MCF-7 cells by downregulating the survival signals.
Yan SC; Liu YP; Zhang LY; Qu JL; Xu L; Liu J; Zhang Y; Hou KZ; Teng YE; Qu XJ
Acta Oncol; 2011 Jun; 50(5):693-9. PubMed ID: 21175263
[TBL] [Abstract][Full Text] [Related]
18. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
19. RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF-κB activation and EGFR signaling.
Sirinian C; Papanastasiou AD; Schizas M; Spella M; Stathopoulos GT; Repanti M; Zarkadis IK; King TA; Kalofonos HP
Oncogene; 2018 Sep; 37(37):5101-5114. PubMed ID: 29844572
[TBL] [Abstract][Full Text] [Related]
20. Negative regulation of CD40-mediated B cell responses by E3 ubiquitin ligase Casitas-B-lineage lymphoma protein-B.
Qiao G; Lei M; Li Z; Sun Y; Minto A; Fu YX; Ying H; Quigg RJ; Zhang J
J Immunol; 2007 Oct; 179(7):4473-9. PubMed ID: 17878343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
